Prelude Therapeutics Inc (PRLD)

$0.79 -0.01 (-0.76%)
Market Cap 44.82M
Revenue (ttm) 7.00M
Net Income (ttm) -127.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,816.71%
Debt to Equity Ratio 0.00
Volume 87,100
Avg Vol 165,414
Day's Range N/A - N/A
Shares Out 56.46M
Stochastic %K 19%
Beta 1.22
Analysts Sell
Price Target $3.75

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 467 1280
Address:
175 Innovation Boulevard, Wilmington, United States
Gellener
Gellener Jul. 1 at 12:44 PM
$PRLD catching @ 0.60
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 19 at 6:27 AM
$PRLD Prelude Therapeutics is targeting the toughest cancers with first-in-class degraders. This company could deliver massive returns. https://biotechhealthx.com/biotech-news/is-prelude-prld-the-next-biotech-titan-investors-are-watching-this-stock-closely/
0 · Reply
Jaybird827
Jaybird827 Jun. 9 at 10:55 PM
$PRLD anyone have an idea of why this is running? Thanks
0 · Reply
Dizzier47
Dizzier47 Jun. 9 at 10:02 PM
$PRLD money coming into biotech stocks again, if this company has good data on their drugs it's rocketing
0 · Reply
Nakuneballe
Nakuneballe Jun. 9 at 6:10 PM
$PRLD patience is key 🙏
0 · Reply
elitechrisvp
elitechrisvp Jun. 9 at 5:47 PM
$TPST good day! $IBRX $PRLD
0 · Reply
elitechrisvp
elitechrisvp Jun. 9 at 5:38 PM
$PRLD 😁👍
0 · Reply
BobBijawklah
BobBijawklah Jun. 4 at 5:26 PM
$BMEA next runner is $PRLD. cash value 2.20 cent share trading at 1.00 dollar . just broke the dollar mark
1 · Reply
Windowphil
Windowphil May. 27 at 1:12 PM
$PRLD lots of insider buying, CEO did well at a previous company
0 · Reply
garygb
garygb May. 26 at 7:43 PM
$PRLD I like the Analysts bullishness.
0 · Reply
Latest News on PRLD
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Jun 2, 2025, 7:30 AM EDT - 4 weeks ago

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 4:05 PM EDT - 2 months ago

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025, 7:30 AM EDT - 2 months ago

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Prelude Announces Presentations at 2025 AACR Annual Meeting

Apr 25, 2025, 4:05 PM EDT - 2 months ago

Prelude Announces Presentations at 2025 AACR Annual Meeting

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Mar 10, 2025, 7:30 AM EDT - 4 months ago

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 7:30 AM EST - 4 months ago

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Dec 11, 2024, 7:30 AM EST - 7 months ago

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Nov 27, 2024, 7:30 AM EST - 7 months ago

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Oct 24, 2024, 7:30 AM EDT - 9 months ago

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Oct 9, 2024, 7:30 AM EDT - 9 months ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 13, 2024, 10:00 AM EDT - 10 months ago

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Sep 9, 2024, 7:30 AM EDT - 10 months ago

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:01 AM EDT - 11 months ago

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 9, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Apr 9, 2024, 4:35 PM EDT - 1 year ago

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 1 year ago

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Feb 29, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Prelude Therapeutics Announces $25 Million Private Placement

Dec 11, 2023, 9:34 AM EST - 1 year ago

Prelude Therapeutics Announces $25 Million Private Placement

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Nov 1, 2023, 4:10 PM EDT - 1 year ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Oct 14, 2023, 12:30 PM EDT - 1 year ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Aug 29, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 31, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 17, 2023, 4:08 PM EDT - 2 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

May 8, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Apr 27, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Feb 9, 2023, 9:05 AM EST - 2 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Nov 14, 2022, 8:00 AM EST - 2 years ago

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

May 10, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Prelude Therapeutics Reports Full Year 2021 Financial Results

Mar 16, 2022, 7:30 AM EDT - 3 years ago

Prelude Therapeutics Reports Full Year 2021 Financial Results

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Mar 11, 2022, 8:00 AM EST - 3 years ago

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Mar 9, 2022, 8:05 AM EST - 3 years ago

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Feb 11, 2022, 7:00 AM EST - 3 years ago

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Jan 4, 2022, 7:00 AM EST - 3 years ago

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

Nov 23, 2021, 7:00 AM EST - 3 years ago

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

Nov 12, 2021, 8:00 AM EST - 3 years ago

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

Nov 8, 2021, 9:00 AM EST - 3 years ago

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Oct 7, 2021, 12:55 PM EDT - 4 years ago

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Oct 7, 2021, 9:00 AM EDT - 4 years ago

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

Aug 12, 2021, 7:30 AM EDT - 4 years ago

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

Why BofA Is Turning Bullish On Prelude Therapeutics

Jul 27, 2021, 12:32 PM EDT - 4 years ago

Why BofA Is Turning Bullish On Prelude Therapeutics

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

May 11, 2021, 7:30 AM EDT - 4 years ago

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences

Mar 3, 2021, 7:00 AM EST - 4 years ago

Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences

Gellener
Gellener Jul. 1 at 12:44 PM
$PRLD catching @ 0.60
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 19 at 6:27 AM
$PRLD Prelude Therapeutics is targeting the toughest cancers with first-in-class degraders. This company could deliver massive returns. https://biotechhealthx.com/biotech-news/is-prelude-prld-the-next-biotech-titan-investors-are-watching-this-stock-closely/
0 · Reply
Jaybird827
Jaybird827 Jun. 9 at 10:55 PM
$PRLD anyone have an idea of why this is running? Thanks
0 · Reply
Dizzier47
Dizzier47 Jun. 9 at 10:02 PM
$PRLD money coming into biotech stocks again, if this company has good data on their drugs it's rocketing
0 · Reply
Nakuneballe
Nakuneballe Jun. 9 at 6:10 PM
$PRLD patience is key 🙏
0 · Reply
elitechrisvp
elitechrisvp Jun. 9 at 5:47 PM
$TPST good day! $IBRX $PRLD
0 · Reply
elitechrisvp
elitechrisvp Jun. 9 at 5:38 PM
$PRLD 😁👍
0 · Reply
BobBijawklah
BobBijawklah Jun. 4 at 5:26 PM
$BMEA next runner is $PRLD. cash value 2.20 cent share trading at 1.00 dollar . just broke the dollar mark
1 · Reply
Windowphil
Windowphil May. 27 at 1:12 PM
$PRLD lots of insider buying, CEO did well at a previous company
0 · Reply
garygb
garygb May. 26 at 7:43 PM
$PRLD I like the Analysts bullishness.
0 · Reply
BigSqueezeComing
BigSqueezeComing May. 24 at 11:13 PM
$PRLD new to this stock. why is everyone so bullish? give me reason to invest
0 · Reply
PenkeTrading
PenkeTrading May. 14 at 1:19 PM
I found you a MACD Bearish Reversal Divergence on the daily chart of Prelude Therapeutics Inc. $PRLD #Prelude #BearishReversalDivergence #NASDAQ
0 · Reply
JBurckhardt
JBurckhardt May. 13 at 9:41 PM
$ABCL partner $PRLD (underrated and undervalued) ended the day up 13%
0 · Reply
Windowphil
Windowphil May. 13 at 3:40 PM
$NKGN don’t sleep on $PRLD, analysts have it going to $5
1 · Reply
Nakuneballe
Nakuneballe May. 13 at 3:27 PM
$PRLD
0 · Reply
BobBijawklah
BobBijawklah May. 13 at 2:41 PM
$PRLD This will run to mid 2s this week. Strong pipeline and strong leadership in CEO Kris Vadhi former INCYTE CEO who developed Jakfi the number one drug in its class.
0 · Reply
Windowphil
Windowphil May. 13 at 2:30 PM
$SMCI $PRLD should explode soon, analyist say it can go to $5+
0 · Reply
RETAlerts
RETAlerts May. 13 at 2:23 PM
The momentum is building for $PRLD at 1.032, now up since our initial alert. Keep an eye on this one, as it could be primed for further gains. (15 minute delay)
0 · Reply
Dizzier47
Dizzier47 May. 13 at 2:13 PM
not selling until 12$ $PRLD
0 · Reply
BobBijawklah
BobBijawklah May. 13 at 2:11 PM
$HCWB $PRLD prelude therpautics is moving could run to 2-3 dollars very short time cash on hand is in the low two just broke 1 dollar. Move fast is running
0 · Reply
BobBijawklah
BobBijawklah May. 13 at 2:09 PM
$PRLD its about time lets go Vaddhi lets send this to three dollars.
0 · Reply
Rick2058
Rick2058 May. 13 at 11:38 AM
$PRLD as per americanbulls technical analysis BUY level met May 12
0 · Reply